Wealthcare Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Wealthcare Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-41	Closed	-$9K	–	651
2021 Q1	$9K	Buy	+41	New	+$9.01K	﹤0.01%	297
2020 Q1	–	Sell	-19	Closed	-$4K	–	640
2019 Q4	$4K	Buy	+19	New	+$3.85K	﹤0.01%	339
2018 Q4	–	Sell	-33	Closed	-$6K	–	205
2018 Q3	$6K	Hold	33	–	–	﹤0.01%	165
2018 Q2	$6K	Hold	33	–	–	﹤0.01%	160
2018 Q1	$5K	Hold	33	–	–	﹤0.01%	162
2017 Q4	$5K	Buy	+33	New	+$4.89K	﹤0.01%	157
2015 Q2	–	Sell	-14	Closed	-$2K	–	848
2015 Q1	$2K	Buy	+14	New	+$1.68K	﹤0.01%	832

Other funds holding VRTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Wealthcare Capital Management's VRTX Position: Q2 2021 in Review

Wealthcare Capital Management sold out of Vertex Pharmaceuticals (VRTX) in Q2 2021, closing a stake of 41 shares — an estimated $9K sold.

Wealthcare Capital Management first reported a position in VRTX in Q1 2015 and held it in 7 quarters. The position peaked at $9K in Q1 2021. 976 funds tracked by Wall St. Rank hold VRTX as of Q2 2021.

Wealthcare Capital Management reported no remaining Vertex Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
Wealthcare Capital Management sold 41 Vertex Pharmaceuticals shares in Q2 2021, an estimated $9K.
Wealthcare Capital Management first reported a position in Vertex Pharmaceuticals in Q1 2015 and held it in 7 quarters.
Wealthcare Capital Management's Vertex Pharmaceuticals position peaked at $9K in Q1 2021.
976 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2021.

Based on Wealthcare Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.